|
Disease Assessment and Progression as Evaluated by RECIST
1.1
Response Evaluation Criteria in Solid Tumors.
Can be Used to Evaluate the Change in tumor Burden in
Response to Therapy
| Item |
RECIST 1.1 (2009). Changes from RECIST 1.0 (2000). |
| Measuring tumor burden |
For Response, 5 targets (2 per organ) |
| Lymph Node |
- Measure short axis
- Define Normal Size
|
| Progression Defined |
20% increase and at least 5mm absolute increase. |
| Non-Measurable Disease |
Expanded definition to convey impact on overall burden of
disease. |
| Confirmation |
Required when response is the primary endpoint, but not PFS. |
| New Lesions |
New section which includes comment on FDG PET. |
PFS: Progression-free Survival.
FDG-PET: 18F-flurodeoxyglucose
Positron Emission Tomography.
RECIST Version 1.1
Response Evaluation Criteria in Solid Tumors.
The new version of RECIST (version 1.1) has been presented at the 20th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in
Geneva, Switzerland (21-24 October 2008):
Presentation available here
The revised RECIST guidelines (version 1.1) are available here for free with
permission from the European Journal of Cancer (EJC). The guidelines and
accompanying articles were published in a special issue of EJC in January
2009(1).
Please download the guidelines here (pdf).
(EORTC = European Organization
for Research and Treatment of Cancer).
(1) E.A. Eisenhauera, P.
Therasseb, J. Bogaertsc, L.H. Schwartzd, D. Sargente, R. Fordf, J. Danceyg,
S. Arbuckh, S. Gwytheri, M. Mooneyg, L. Rubinsteing, L. Shankarg, L. Doddg,
R. Kaplanj, D. Lacombec, J. Verweijk, New response evaluation criteria in
solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer
45(2009) 228-247.
Created 7/20/2009 Howard Hansen
|
